

Date: 14th November, 2024

To,
BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001.
Scrip Code: 511523

Sub.: Unaudited Financial Results for the quarter and half year ended September 30, 2024

Dear Sir,

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

1. Statement showing the Unaudited Financial Results for the quarter and half year ended September 30, 2024.

2. Limited Review Report on the Unaudited Financial Results for the quarter and half year ended September 30, 2024.

Thanking You.

Yours faithfully, For Veerhealth Care Limited

Bhavin S. Shah Managing Director DIN: 03129574

Encl: As above



Regd Office: 629-A, Gazdar House, 1st Floor, J.S.S. Marg, Near Kalbadevi Post Office, Mumbai - 400002. Tel. No. 022-22018582 CIN: L65910MH1992PLC067632

Email: info@veerhealthcare.net Website: www.veerhealthcare.net

Statement of Unaudited Financial Results for the Quarter and Half Year ended September 30, 2024

(Rs. in lakhs) Standalone Sr. No. Particulars Half year ended Ouarter ended Quarter ended Ouarter ended Half year ended Year ended 30-09-2023 30-09-2024 30-06-2024 30-09-2024 31-03-2024 30-09-2023 Unaudited Unaudited Unaudited Unaudited Unaudited Audited 740.92 Revenue from operations 514.71 206.45 382.79 721.16 1322.31 II 24.76 35.81 41.51 60.58 56.02 138.98 Other Income III Total Revenue (I + II) 539.47 242.26 424.30 781.74 796.94 1461.29 IV Expenses: (a) Cost of materials consumed 0.00 0.00 0.00 0.00 0.00 0.00 (b) Purchase of stock-in-trade 271.93 298.77 291.08 570.70 485.50 791.89 (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -34 58 0.63 25.66 -171.27 -145.61 120.97 (d) Employee benefits expense 38.53 32.27 30.61 70.80 58.80 131.03 (e) Finance Costs 11.08 0.24 0.16 11.32 0.17 0.76 (f) Depreciation and amortisation expense 20.12 19.10 17,56 39.22 35.11 71.15 (g) Other expenses 130.27 48.01 74.22 178.29 131.24 217.19 227.12 711.45 1332.99 Total Expenses 497.59 379.05 724.72 Profit/(Loss) before exceptional items (III - IV) 41.88 15.14 45.25 57.02 85.49 128.30 VI 0.00 0.00 0.00 0.00 Exceptional items 0.00 0.16 Profit before tax (V - VI) 85.49 VII 41.88 15.14 45.25 57.02 128.14 VIII Tax expense: 1) Current Tax 12.00 3.00 6.00 15.00 12,00 28.50 0.00 0.00 0.00 0.00 2) Prior Year Tax 0.00 0.00 2) Deferred Tax 0.00 0.00 0.00 0.00 0.00 59.04 Profit/(Loss) for the period (VII - VIII) 29.88 39.25 42.02 73.49 40.60 IX 12.14 X Other Comprehensive Income 0.00 -2.21 0.76 (a) Items that will not be reclassified to Profit or Loss 0.00 0.00 -1.11 (b) Income Tax effect on above 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.11 0.00 -2.21 0.76 Other Comprehensive Income 0.00 71.28 Total Comprehensive Income for the period (IX + X)29.88 12,14 38.14 42.02 41.36 XII Paid-up equity share capital of Rs. 10 each 1999.85 1999.85 1999.85 1999.85 1999.85 1999.85 XIII 226.05 219.03 184.03 Other Equity XIV Net Worth 2225.90 2218.88 2183.88 XV Earnings Per Share (of Rs. 10 each): 0.36 0.21 (a) Basic (in Rs.) 0.15 0.06 0.19 0.21

The Mumbal of Mumbal of

0.21

0.36

0.21

0.19

0.06

0.15

(b) Diluted (in Rs.)

Regd Office: 629-A, Gazdar House, 1st Floor, J.S.S. Marg, Near Kalbadevi Post Office, Mumbai - 400002.

Tel. No. 022-22018582 CIN: L65910MH1992PLC067632

Email: info@veerhealthcare.net Website: www.veerhealthcare.net

#### NOTES:

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14th November, 2024. The Limited Review under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the Statutory Auditors. The limited review report does not contain any observation which would have an impact on the above results.
- The standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- 3 During the quarter ended September 30, 2024, the Company is operating in a single segment i.e. 'Healthcare Pharma Products'. Accordingly, segment wise reporting is not applicable.
- 4 Figures of the previous periods have been rearranged / regrouped, wherever necessary.
- 5 The financial results of the Company are available at www.bseindia.com and at www.veerhealthcare.net.

By order of the Board For Veerhealth Care Limited

> Bhavin S. Shah Managing Director DIN: 03129574

Place: Mumbai Date: 14th November, 2024

Regd Office: 629-A, Gazdar House, 1st Floor, J.S.S. Marg, Near Kalbadevi Post Office, Mumbai - 400002. Tel. No. 022-22018582 CIN: L65910MH1992PLC067632

Email: info@veerhealthcare.net Website: www.veerhealthcare.net

#### Statement of Assets and Liabilities

(Rs. in lakhs)

	Particulars	As at	As at
	rarticulars	30-09-2024	31-03-2024
-		Unaudited	Audited
A	ASSETS	Chaudited	Audited
	Non-Current Assets		*
1		1481.29	1196.8
	(a) Property Plant & Equipment	1481.29	1196.8
	(b) Capital work in progress	*	
	(c) Investment Property	-	-
	(d) Intangible assets under development	- 1	
	(e) Financial Assets		
	(i) Investments	-	
	(ii) Trade receivables	-	0.2
	(iii) Loans	-	-
	(iv) Others	230.15	209.7
	(f) Deferred Tax Asset (Net)	-	
	(g) Other Non-Current Assets	121.36	59.1
	Total Non-Current Assets	1832.80	1466.0
2	Current Assets		
	(a) Inventories	285.21	139.6
	(b) Financial Assets	200.21	103.0
	(i) Investments	30.85	
	(ii) Trade receivables	298.39	392.0
	A V Comment of the co		
	(iii) Cash & cash equivalents	48.75	23.8
	(iv) Bank Balances other than (iii) above		
	(v) Loans	565.33	739.8
	(vi) Others	-	
	(c) Current Tax Assets (Net)	-	
	(d) Other Current Assets	35.36	50.3
	Total Current Assets	1263.89	1345.6
	TOTAL ASSETS	3096.69	2811.68
3	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity Share Capital	1999.85	1999.8
	(b) Other Equity	226.05	184.0
	Total Equity	2225.90	2183.8
2	Non-Current Liabilities (a) Financial Liabilities		
	(i) Borrowings		
		-	
	(ii) Trade Payables	-	
	(iii) Others		
	(b) Provisions	70.98	37.7
	(c) Deferred Tax Liabilities (net)	73.61	73.6
	(d) Other Non-Current Liabilities	390.99	239.1
	Total Non-Current Liabilities	535.58	350.4
3	Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Trade Payables	308.56	215.5
	(iii) Other Financial Liabilities	-	-
	(b) Other Current Liabilities	11.65	28.5
	(c) Provisions	15.00	33.2
	Total Current Liabilities	335.21	277.3
	Total Current Liabilities	333.21	211.3.
	TOTAL FOURTY AND HARRITIES	3096.69	2811.68
	TOTAL EQUITY AND LIABILITIES	3090.09	2011.00

By order of the Board For Veerhealth Care Limited

MUMBAI LA SON WAREN

Bhavin S. Shah Managing Director DIN: 03129574

Place: Mumbai Date: 14th November, 2024

Regd Office: 629-A, Gazdar House, 1st Floor, J.S.S. Marg, Near Kalbadevi Post Office, Mumbai - 400002. Tel. No. 022-22018582 CIN: L65910MH1992PLC067632

Email: info@veerhealthcare.net Website: www.veerhealthcare.net

Cash Flow Statement for six months ended September 30, 2024

(Amount in lakhs)

Particulars	Six months ended	Six months ended
raiticulais	CARCAMONAL RESERVED	September 30, 2023
(A) CASH FLOW FROM OPERATING ACTIVITIES	September 30, 2024	September 30, 2023
Profit Before Tax	57.02	85.4
Adjustments for:	37.02	03,4:
Depreciation	39.22	35.1
Other Comprehensive Income	0.00	
Interest and finance charges	11.32	
Interest income	(44.71)	
Operating profit before working capital changes	62.85	
Adjustments for changes in working capital:	02.00	100.5
(Increase)/decrease in other non current financial assets	(20.42)	1.34
(Increase)/decrease in other non current assets	(62.19)	1000
Increase in inventories	(145.61)	
(Increase)/decrease in trade receivables, current	93.65	
(Increase)/decrease in trade receivables, non-current	0.22	K310 154155
(Increase)/decrease in Balances other than (ii)	0.00	
(Increase)/decrease in loans	174.49	
(Increase)/decrease in other current financial assets	0.00	V
(Increase)/decrease in current tax assets	0.00	
(Increase)/decrease in other current assets	15.01	
Increase/(decrease) in provisions, current	(18.21)	
Increase/(decrease) in provisions, non-current	33.22	, , , , , , , , , , , , , , , , , , , ,
Increase /(decrease) in trade payables, current	93.05	
Increase /(decrease) in trade payables, non-current	0.00	
Increase /(decrease) in other non current liabilities	151.87	(255.50
Increase /(decrease) in other current liabilities	(16.94)	8.77
Cash generated from/(used in) operations	360.99	
Income taxes paid (net of refund)	(15.00)	(12.00
Net cash flow from /(used in) operating activities	345.99	(244.96
(B) CASH FLOW FROM INVESTING ACTIVITIES		
Payment for purchase of property, plant and equipment	(323.63)	(17.01)
Purchase of Investments	(30.85)	0.00
Interest received	44.71	16.04
Net cash flow from/(used in) investing activities	(309.77)	(0.97)
(C) CASH FLOW FROM FINANCING ACTIVITIES		
Payment of long term borrowings	0.00	0.00
Proceeds/(repayment) from short term borrowings (net)	0.00	0.00
Additions in share capital	0.00	999.92
Net increase in other equity	0.00	(999.92
interest and finance charges paid	(11.32)	(0.17)
Net cash flow from financing activities	(11.32)	(0.17)
Net change in cash and cash equivalents (A+B+C)	24.90	(246.10)
Cash and bank balances at the beginning of the year	23.85	361.24
Cash and bank balances at the end of the year	48.75	115.14



# **Limited Review Report**

## To the Board of Directors of Veerhealth Care Limited

I have reviewed the accompanying statement of Unaudited Standalone Ind-AS Financial Results of M/s. Veerhealth Care Limited ("the Company") for the quarter and half year ended 30<sup>th</sup> September, 2024, together with the notes thereon attached herewith ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.

This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

I conducted my review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that I plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement.

A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an Audit. I have not performed an audit and accordingly I do not express an audit opinion.

Based on my review conducted as above, nothing has come to my attention that causes me to believe that the accompanying statement of Audited standalone Ind-AS financial results prepared in accordance with applicable Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Jayesh R Shah & Co.

**Chartered Accountants** 

Firm Regn. No.104182W SHR. SA

Jayesh Shah Proprietor

Membership No.033864

Place: Mumbai

Date: 14<sup>th</sup> November, 2024 UDIN: 24033864BKEYML1940

M, NO. 033864 FRN

04182W